Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

Complete Pathological Response Following Radiochemotherapy for Locally Advanced Rectal Cancer: Short and Long-term Outcome

OTHMAN ISKANDER, LISE COURTOT, NICOLAS TABCHOURI, ALICE ARTUS, NICOLAS MICHOT, OLIVIER MULLER, URS PABST-GIGER, PASCAL BOURLIER, AURORE KRAEMER-BUCUR, THIERRY LECOMTE, SERGE GUYETANT, SOPHIE CHAPET, GILLES CALAIS, EPHREM SALAMÉ and MEHDI OUAÏSSI
Anticancer Research September 2019, 39 (9) 5105-5113; DOI: https://doi.org/10.21873/anticanres.13705
OTHMAN ISKANDER
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LISE COURTOT
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLAS TABCHOURI
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
ALICE ARTUS
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
NICOLAS MICHOT
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
OLIVIER MULLER
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
URS PABST-GIGER
2Department of General-, Visceral- and Transplant Surgery, University of Münster, Münster, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PASCAL BOURLIER
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
AURORE KRAEMER-BUCUR
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
THIERRY LECOMTE
3Department of Hepatogastroenterology and Digestive Oncology, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SERGE GUYETANT
4Department of Histopathology, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SOPHIE CHAPET
5Department of Radiotherapy, Bretonneau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GILLES CALAIS
5Department of Radiotherapy, Bretonneau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
EPHREM SALAMÉ
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MEHDI OUAÏSSI
1Department of Digestive, Oncological, Endocrine, Hepato-Biliary, Pancreatic and Liver Transplant Surgery, Trousseau Hospital, Tours, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: m.ouaissi@chu-tours.fr
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background/Aim: Preoperative radiochemotherapy (RCT) followed by total mesorectum excision has become the gold standard for locally advanced carcinoma of the low and middle rectum. The aim of the study is to evaluate the short and long-term outcomes of patients in complete pathological response (PR) following this treatment sequence. Patients and Methods: One hundred and thirty patients were retrospectively included between 2005 and 2017 in an expert centre, with 3 groups formed, according to the PR: i) complete PR (absence of tumour cells on the surgical specimen ypT0N0), ii) partial PR (T or N downsizing) and iii) without PR. Results: The complete PR rate was 13.1%. The complete PR group tended to develop less symptomatic fistulas compared to partial PR and without PR groups (5.8% versus 13.5% versus 18.7, respectively; p=0.607). The 5-year disease-free survival was increased for complete-PR patients (93% versus 79% versus 47%, respectively; p=0.0003) without an improvement in overall survival. Conclusion: Complete PR is associated with an improvement in survival without recurrence and without an improvement in the overall survival at 5 years.

  • Rectal carcinoma
  • radiochemotherapy
  • pathological response

The management of rectal carcinoma has evolved over the last twenty years and is now well standardized (1). Preoperative radiochemotherapy (RCT) followed by proctectomy with total mesorectal excision (TME) is the gold standard for locally advanced rectal carcinoma (2-4). This new management allows a strong decrease of the local recurrence rate (from 16.5% to 8.2%, p<0.001) and an improvement of the disease free survival (from 65.8% to 77.3%, p<0.001) (3-5). Adding a neoadjuvant treatment by preoperative RCT for locally advanced mid- or low tumour has improved local tumour control. RCT has resulted in a positive response with downstaging in 2/3 of patients and a complete pathological response (cPR) in 1/5 of patients (3, 6, 7). cPR is associated with a decrease in local recurrence, and improvement of disease-free survival (8-10). This breakthrough has not only allowed a decrease in the recurrence rate, but has also offered better outcomes from the anal sphincteric preservation technique (and consequently a decrease in the abdominoperineal resection rate) (11). Some conflicting results have been reported concerning the impact of cPR on the overall survival (9, 12). Similarly, the correlation between cPR and neoadjuvant therapy is still debated, particularly with regard to anastomotic leakage. Magggiori et al., showed that patients without complete cPR have more symptomatic anastomotic fistula while Landi et al., have not found this association (13, 14). To our knowledge, few studies have examined the relationship between cPR and the functional outcomes following proctectomy with neoadjuvant RCT. Thus, the impact of the pathological response (PR) on postoperative morbidity and oncological and functional outcomes are yet to be clarified.

The aim of this study is to evaluate short- and long-term outcomes for patients with a complete pathological response following neoadjuvant radiochemoterapy and total mesorectal excision for locally advanced rectal cancer.

Patients and Methods

Population and study design. From January 2005 to December 2017, 600 consecutive patients underwent elective rectal resection for rectal cancer in our department. One hundred and thirty patients (21%) for locally advanced rectal adenocarcinoma biopsy proven with cT3, T4 or TxN+, bulky T2 or anterior T2 by radiologic examination (magnetic resonance imaging and/or endo-ultrasound) of the mid, lower and upper rectum who had received neoadjuvant RCT, were reviewed. All patients were preoperatively treated by neoadjuvant RCT. The exclusion criteria were: i) rectal cancer with synchronous metastasis, ii) previous surgery of the left sided colon and iii) local or abdominoperineal resection or Hartmann's procedure required. Data collection included: i) demographic variables, ii) operative and iii) postoperative features.

Preoperative work-up. Data were retrospectively retrieved from medical records. Demographic features (gender, age at time of surgery, body mass index, comorbidity and ASA score), tumour evaluation before neoadjuvant treatment, pathological and oncological results were collected. Tumour evaluation was based on physical examination using: i) digital rectal exam and anoscopy, ii) total colonoscopy with biopsy, iii) endorectal ultrasound (EUS) and/or iv) pelvic magnetic resonance imaging (MRI), as well as v) computed thoracoabdominal (CT).

Neoadjuvant treatment: radiochemotherapy. All patients received preoperative external beam megavoltage radiation therapy at a total dose of 45 to 50.4 Gy, delivered in daily 1.8- to 2.1-Gy fractions 5 days per week over a 5-6 week period. Pelvic volume was defined based on tumour characteristics, mesorectum, the ventral side of the sacrum and the hypogastric vessels. L5 and S1 vertebrae determined the upper limit, while the levator ani muscle or the anal verge determined the lower limit. Preoperative chemotherapy was concomitantly administered to all patients (oral 5-FluoroUracyl (Capecitabin, Xeloda®, 825 mg/m2/day, twice a day) (15).

Surgical procedure. All patients underwent mechanical bowel preparation before surgery (16). Laparoscopy was the standard approach except for patients presented with T4 tumour or those considered unfit for laparoscopic approach. A medial to lateral approach was performed, with the operative procedure routinely involving high ligation of the inferior mesenteric vessels, complete mobilization of the splenic flexure, and TME (1). Proximal colon was transected by linear stapler, 10 cm above the lesion. The type of anastomosis was left to the discretion of the surgeon. Sphincteric preservation was performed when necessary. A temporary loop ileostomy was performed in all cases, and a pelvic single suction drain was placed behind the anastomosis for 48-72 hours in all cases. A protective stoma was closed 6 to 8 weeks postoperatively if CT-scan with water-soluble enema did not show any evidence of anastomotic leakage.

Pathological findings. Surgical specimens were analysed using a standardized protocol (17). Histological evaluation consisted on: i) ypTNM staging, ii) circumferential and longitudinal margins (R0, R1 and R2, for complete, microscopically and macroscopically incomplete resections, respectively), iii) completeness of mesorectum resection, iv) degree of colloid component, v) differentiation grade, vi) presence of vascular, lymphatic or perinervous emboli. An involved circumferential resection margin (CRM) was defined as ≤1 mm between the deepest tumour invasion and the margin of surgical resection inked previously. This included a tumour within a lymph node, as well as a direct tumour extension. Acellular pools of mucin at the level of the CRM following neoadjuvant radiochemotherapy were considered as a negative CRM (18). PR was obtained by comparing tumour and node staging (cTNM) before RCT to postoperative histological analysis (ypTNM). Three groups were defined as follows: i) complete pathological response (cPR), ii) absence of tumour cell in the surgical specimen (ypT0N0), iii) partial pathological response (pPR) (T or N downstaging) and without pathological response (wPR).

Short-term outcomes. Postoperative morbidity and mortality were defined as events occurring during hospital stay or within 30 postoperative days. Postoperative complications were ranked according to the international Clavien Classification (19). Severe morbidity was defined as Dindo 3 or greater. In-hospital stay was measured from the time of surgery to the date of discharge from the hospital. Post-operative complications have been divided into: i) abdominal complications (e.g. fistula, collection, wound abscess, ileus etc.) and ii) extra-abdominal complications (e.g. urinary tract disease, pulmonary embolism, etc.). Anastomotic leakage (AL) was defined according to the International Study Group of Rectal Cancer (20). Symptomatic fistula requiring modification of management (medical, radiological or surgical) have been differentiated from asymptomatic fistula (diagnosed on enema-contrast CT-scan, routinely performed 6 to 8 weeks postoperatively, before considering stoma reversal). Any clinical (sepsis, peritonitis, emission of gas, pus, or faeces from the pelvic drain, purulent discharge per anus, or rectovaginal fistula) and/or biological suspicion of AL led to an early CT-scan assessment. Symptomatic AL management included antibiotics, radiologic or transanal drainage, and/or early abdominal redo surgery (13). In asymptomatic AL, stoma reversal was postponed and enema-contrast CT was repeated until AL tract was no longer seen. If asymptomatic AL persisted >6 months postoperatively, protective stoma reversal was performed, as was described recently (21).

Long-term outcomes. Long-term functional and oncological outcomes were recorded for all patients. Patient follow-up was performed every 3 months for the first 2 postoperative years, every 6 months for the next 3 years, and annually thereafter. Follow-up was updated until December 2018 and consisted of clinical examination, CT-scan and blood samples with colonoscopy performed 1 year following surgery and then every 3 years. Follow-up data was obtained from medical records of the outpatient clinic or through phone interviews. Local recurrence was defined as tumour recurrence at the anastomotic site or in the pelvic cavity, while distant recurrence was defined as tumour recurrence beyond the loco-regional area, including liver, lung and other extrapelvic sites. Surviving patients were assessed for disease recurrence and site of recurrence. Long-term functional genito-urinary and digestive outcomes, as well as quality of life assessments were recorded using a French translation of the low anterior resection score (LARS) and the Wexner continence grading scale (22, 23). Overall, 8 (6.2%) patients had a follow-up of less than 6 months and 18 (13.8%) a follow-up of less than 12 months.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Study population (n=130) demographic data.

Statistical analysis. Statistical analyses were performed using SPSS version 20.0 (SPSS Inc., Chicago, IL, USA). All tests were two-sided and statistical significance was accepted at the 0.05 level. Continuous variables are expressed as their medians and ranges (min, max) and were compared using ANOVA or nonparametric ANOVA tests, accordingly. Categorical variables are reported as numbers and percentages and were compared using the χ2 test with Bonferroni correction whenever necessary. The Kaplan-Meier method was used to estimate recurrence-free survivals (RFS) and overall survivals (OS), which were compared using the Log-rank test. This study was conducted according to the ethical standards of the Committee on Human Experimentation of our institution and were reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines (24).

Results

One hundred and thirty patients with locally advanced rectal carcinoma who underwent curative intent neoadjuvant RCT and rectal resection with total or partial mesorectum excision were included. According to the aim of the study, three groups of patients were identified: i) wPR group 24.6% (n=32), ii) pPR group 62.3% (n=81) and iii) cPR group 13.1% (n=17).

Demographic and tumour characteristics. Demographic data and carcinoma features and comparison between the three groups are summarized in Table I. There were 44 males (33.8%) with a median age of 65.5 years (37-84). According to the ASA score, patients' comorbidities were comparable between the three groups (p=0.646). One hundred and thirty patients who underwent sphincteric-preservation resection with curative intent for upper 20.7% (n=27), mid 53.1% (n=69) and low 26.1% (n=34) rectal adenocarcinoma were included. The rate of low rectal tumour was higher in the cPR group (58.8% versus 23.4% versus 15.6% for cPR, pPR, wPR, respectively; p=0.014). Concerning tumour staging in the whole cohort the rates were: 6.9% uT2, 89.2% uT3, 3.8% uT4. Nevertheless, there a higher rate of uT3 in the pPR group compare to wPR and cPR group (92.6% versus 87.5% versus 76.5%; p=0.029). The rate of nodes invaded was 77.7% (n=101), and the group with pPR had a higher rate of nodes invaded compared to the other two groups (86.4% versus 62.5 versus 64.7% for pPP, wPR, cPR, respectively; p=0.004).

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

Surgical procedure and short-term outcomes.

Surgery and short-term outcomes. Intraoperative parameters are reported in Table II. Laparoscopic resection was performed in 92.3% (n=120) of patients with comparable rates between the three groups (p=0.898). The total mesorectal excision was complete in 74.6% (n=97) of patients with no difference found between both groups (p=0.132). Overall, conversion was required in 23.1% (n=30) of patients and there was no difference between the three groups. Latero-terminal anastomosis was performed in 51.5% (n=67) of patients and manual colo-anal anastomosis was performed in 14.6% (n=19) of patients with no statistical difference found between the three groups (p=0.601, and p=0.638, respectively). Postoperative details are also reported in Table II. Thirty-day mortality rate was nil. Overall complication rate was 38.5% (n=50) for the whole series without difference between the three groups. A fraction of patients 12.3% (n=16) experienced severe postoperative complications (grade III-IV). AL occurred in 20% (n=26) of patients, including 13.8% of patients (n=18) with a symptomatic leak. AL was more frequent, although statistically not significant, in the wPR group (21.8%).

Redo abdominal surgery was performed after an averageof 7 (3-22) days in 15.4% (n=20) of patients (anastomosis resection and/or colostomy placement, n=5 and peritoneal lavage or transanal drainage, n=15). Trans-anal drainage under general anesthesia was performed in 2.3% (n=3) of patients. Overall, 15.4% (n=20) of patients were managed with antibiotics only.

Pelvic collections were present in 10% (n=13) of patients, 15.6% (n=5) of which belonged in the wPR group while 8.6% (n=7) were in the pPR and 5.8% (n=1) in the cPR group (p=0.446). The overall rate of permanent stoma was 14.6% with no difference found between wPR, pPR and cPR groups (p=0.292). The hospital average length of stay was 12 (6-77) days and there was no difference between the three groups.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Overall survival in the three groups: i) without pathological response (wPR; black line), ii) group with partial pathological response (pPR; red), and iii) group with complete pathological response (cPR; blue).

Long-term outcomes. The median follow up was about 45.3 (4.4-151) months. Three and five-year overall and disease-free survivals were 95:83% and 75.7:72.5%, respectively. Three- and five-year overall survival was not different between the three groups (96:89% wPR, 95:86% pPR, 100:100% cPR; p=0.392), as shown in Figure 1. Three- and five-year disease-free survival was statistically different between the three groups (51:47% wPR, 82:79% pPR, 93:93% cPR, p=0.0003). There were 19 (14.6%) patients requiring permanent stoma without any difference in the three groups. Analysis of long-term functional results was available in 20 patients. Excluding deceased patients (n=16) and patients with a permanent stoma placement (n=19), this represented a 21.05% response rate for functional assessment scores. Only the Wexner continence and LARS grading scales were not different between the groups. Overall, the functional results were disappointing. The results are not significant but some trends may be noted. Over the entire series, 65% (n=13) of patients had a major LARS, all patients (n=4) with complete PR had a major LARS unlike the 2 patients without PR who had a minor LARS. Concerning faecal incontinence, 55% (11) of patients had minimal to moderate incontinence, 45% (9) had important to severe incontinence and no patient reported normal continence (Table III).

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Disease free survival in the three groups: i) without pathological response (wPR; black line), ii) group with partial pathological response (pPR; red), and iii) group with complete pathological response (cPR; blue).

Discussion

It is now established that neoadjuvant radio chemotherapy combined with proctectomy and TME is the standard treatment for cancer of the low and mid rectum. This therapeutic strategy demonstrates a clear anti-tumoral benefit. However, the impact of the pathological response on post-operative morbidity remains debated.

In our cohort of 130 patients, the complete pathological response rate is 13.1%, which is consistent with previous series where the response rate varies from 11.4% to 27% (25, 26). In a recent meta-analysis, the mean rate of pCR after RCT for rectal cancer was found to be about 24.4% (5). The variability between studies is explained by the heterogeneity in defining cPR, stages from ypT0 to ypT0N0 and ypT0N0M0, and the lack of standardised methodology to evaluate the pathological assessment of the tumour response, despite of different grading systems available (27, 28). Moreover, several studies are limited by their small size sample and a short follow-up period, which does not allow analysing the impact of PR on survival.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table III.

Pathological findings, oncological and functional results.

In our study, we found that cPR was associated with an improvement in recurrence-free survival, but without an improvement in overall survival. Recurrence-free survival increased due to a significant reduction in the occurrence of distant metastasis and a not very significant trend towards a decrease in the number of local recurrences. These results are variably reported in literature. Theodoropoulos et al., have observed that disease-free survival improved significantly in cases of cPR and T-downstaging (10). For others, the only complete pathological response was significantly associated with improved disease-free survival, with 5-year disease-free survival rates ranging from 83.4% to 89% for a complete response, compared to 38.6% to 73.4% for a residual tumour (14, 29). Nevertheless, the association between a complete pathological response and overall survival remains unclear. Landi et al., have shown that the 5-year overall survival of patients with complete PR was better compared to those of the non-PR (92.7% versus 75.3%) (14). On the other hand, some authors have not identified any significant association between PR and improved survival (12, 30, 31).

In the absence of distant metastasis, prognosis of locally advanced rectal cancer depends mainly on rectal wall invasion and spread to the mesorectal lymph nodes. The Korean Radiation Oncology Group (KROG) 09-01(KONCLUDE) trial concluded that rectal cancer patients achieving cPR following preoperative RCT had favourable long-term outcomes, whereas a positive ypN status had a poor prognosis, even after the complete regression of the tumour. Five-year disease free and overall survival were about 88.5% versus 45.2% and 94.8% versus 72.8% in case of ypT0N0 or ypT0N+, respectively (p<0.001) (32). Moreover, despite complete regression of the primary rectal wall tumour, residual disease in the mesorectal lymph nodes has been reported to occur in up to 17% of patients (10). The accuracy of lymph node staging is thereby essential, although the performance of current imaging procedures seems to be limited, accuracy rates with EUS, MRI and CT scan have been about 61%, 65%, 62%, respectively (33).

All of our patients were systematically operated five to six weeks following RCT. For this reason we did not analyse the impact of the interval between completion of neoadjuvant RCT and surgery. The time interval between these two procedures is frequently debated. Kalady et al., have reported that an interval greater than or equal to 8 weeks following completion of RCT was the only predictive factor of pCR in their study (34). Tulchinsky et al., have shown that waiting 8 to 24 weeks resulted in higher rates of cPR, whereas Stein et al., have not shown any difference between 4 to 8 and 10 to 14 weeks (35, 36). The recent multicentre French randomized trial (Greccar-6 trial), comparing the periods of 7 versus 11 weeks between the end of RCT and surgery and demonstrated there was no difference (16).

Recently, the notion of organ preservation for locally advanced rectal cancers has emerged. Habr-Gama et al., have shown that pre-operative radiochemotherapy provides a 27% complete clinical response allowing for a “watch and wait” observational strategy (37). Nevertheless, the local recidivism rate is not negligible (17% in the first year), these recurrences are probably initial responses that are ultimately incomplete and are subject to transanal resection. Thus, for locally advanced rectal cancers, the aggressive strategy remains in line with the current state of the literature. Locally advanced cancer must the subject of further prospective studies.

Regarding post-operative outcomes, there was no difference between the groups for overall complication rate, minor complications and severe complications. This is consistent with previous studies that have not shown that patients in complete response have the same overall complication rate, although Maggiori et al., have shown that they have more severe complications (22% versus 6%, p=0.04) (12, 13). Concerning anastomotic fistulas feared following proctectomy, there was again no difference between our groups. However, there is a trend towards a decrease in symptomatic fistula rates in patients with cPR compared to those with pPR and wPR. This could have been consolidated by a larger population. Indeed, Maggiori et al., were the first to report an association between a complete response to neo-adjuvant therapy and a decrease in the occurrence of symptomatic anastomotic fistula (13). In our work, the weakness of our population size did not allow us to draw conclusions about functional results; however, to our knowledge no other study has so far compared functional results according to the pathological response.

This study is limited by its retrospective nature and the size of its population size, which may explain its statistical weakness. On the other hand, patients with upper rectal cancer were included in the same way as patients with cancer in other locations because they receive the same treatment by neoadjuvant radiochemotherapy in our centre upon expert agreement.

We demonstrated that for locally advanced rectal adenocarcinoma patients treated with RCT followed by total mesorectum excision with cPR presented an increased disease-free survival compared to those with pPR or wPR. There was no impact on the overall survival. The post-operative complication rate appeared to be reduced following surgery for patients with cPR.

Acknowledgements

The Authors are deeply grateful to Katarzyna GAJ and Guillaume Proutheau for their invaluable secretarial assistance.

Footnotes

  • ↵* These Authors contributed equally to this study.

  • Authors' Contributions

    Study concept and design was performed by MO, LC, OI and NT, acquisition of data by AA, OI, NM and OM, analysis and interpretation by MO and LC.. Administrative, technical, and material support as well as supervision was done by MO. MO, LC, OI and NT drafted the manuscript, and PB, UGP, AKB, TL, SG, SC, GC, ES and MO critically reviewed the manuscript.

  • Conflicts of Interest

    The Authors have no conflicts of interest to declare.

  • Received July 10, 2019.
  • Revision received July 19, 2019.
  • Accepted July 22, 2019.
  • Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved

References

  1. ↵
    1. Heald RJ,
    2. Husband EM,
    3. Ryall RD
    : The mesorectum in rectal cancer surgery--the clue to pelvic recurrence? Br J Surg 69: 613-616, 1982. PMID: 6751457. DOI: 10.1002/bjs.1800691019
    OpenUrlCrossRefPubMed
  2. ↵
    1. Kapiteijn E,
    2. Marijnen CA,
    3. Nagtegaal ID,
    4. Putter H,
    5. Steup WH,
    6. Wiggers T,
    7. Rutten HJ,
    8. Pahlman L,
    9. Glimelius B,
    10. van Krieken JH,
    11. Leer JW,
    12. van de Velde CJ,
    13. Dutch Colorectal Cancer Group
    : Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 345: 638-646, 2001. PMID: 11547717. DOI: 10.1056/NEJMoa010580
    OpenUrlCrossRefPubMed
  3. ↵
    1. Bosset J-F,
    2. Collette L,
    3. Calais G,
    4. Mineur L,
    5. Maingon P,
    6. Radosevic-Jelic L,
    7. Daban A,
    8. Bardet E,
    9. Beny A,
    10. Ollier J-C,
    11. EORTC Radiotherapy Group Trial 22921
    : Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355: 1114-1123, 2006. PMID: 16971718. DOI: 10.1056/NEJMoa060829
    OpenUrlCrossRefPubMed
  4. ↵
    1. Gérard J-P,
    2. Conroy T,
    3. Bonnetain F,
    4. Bouché O,
    5. Chapet O,
    6. Closon-Dejardin M-T,
    7. Untereiner M,
    8. Leduc B,
    9. Francois E,
    10. Maurel J,
    11. Seitz J-F,
    12. Buecher B,
    13. Mackiewicz R,
    14. Ducreux M,
    15. Bedenne L
    : Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24: 4620-4625, 2006. PMID: 17008704. DOI: 10.1200/JCO.2006.06.7629
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Martin ST,
    2. Heneghan HM,
    3. Winter DC
    : Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer. Br J Surg 99: 918-928, 2012. PMID: 22362002. DOI: 10.1002/ bjs.8702
    OpenUrlCrossRefPubMed
  6. ↵
    1. Mohiuddin M,
    2. Winter K,
    3. Mitchell E,
    4. Hanna N,
    5. Yuen A,
    6. Nichols C,
    7. Shane R,
    8. Hayostek C,
    9. Willett C,
    10. Radiation Therapy Oncology Group Trial 0012
    : Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. J Clin Oncol 24: 650-655, 2006. PMID: 16446336. DOI: 10.1200/JCO.2005.03.6095
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. Ruo L,
    2. Tickoo S,
    3. Klimstra DS,
    4. Minsky BD,
    5. Saltz L,
    6. Mazumdar M,
    7. Paty PB,
    8. Wong WD,
    9. Larson SM,
    10. Cohen AM,
    11. Guillem JG
    : Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236: 75-81, 2002. PMID: 12131088. DOI: 10.1097/00000658-200207000-00012
    OpenUrlCrossRefPubMed
  8. ↵
    1. Quah H-M,
    2. Chou JF,
    3. Gonen M,
    4. Shia J,
    5. Schrag D,
    6. Saltz LB,
    7. Goodman KA,
    8. Minsky BD,
    9. Wong WD,
    10. Weiser MR
    : Pathologic stage is most prognostic of disease-free survival in locally advanced rectal cancer patients after preoperative chemoradiation. Cancer 113: 57-64, 2008. PMID: 18442099. DOI: 10.1002/cncr.23516
    OpenUrlCrossRefPubMed
  9. ↵
    1. Rullier A,
    2. Laurent C,
    3. Capdepont M,
    4. Vendrely V,
    5. Bioulac-Sage P,
    6. Rullier E
    : Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma. Am J Surg Pathol 34: 562-568, 2010. PMID: 20216380. DOI: 10.1097/PAS.0b013e3181d438b0
    OpenUrlCrossRefPubMed
  10. ↵
    1. Theodoropoulos G,
    2. Wise WE,
    3. Padmanabhan A,
    4. Kerner BA,
    5. Taylor CW,
    6. Aguilar PS,
    7. Khanduja KS
    : T-level downstaging and complete pathologic response after preoperative chemoradiation for advanced rectal cancer result in decreased recurrence and improved disease-free survival. Dis Colon Rectum 45: 895-903, 2002. PMID: 12130878.
    OpenUrlCrossRefPubMed
  11. ↵
    1. Sauer R,
    2. Becker H,
    3. Hohenberger W,
    4. Rödel C,
    5. Wittekind C,
    6. Fietkau R,
    7. Martus P,
    8. Tschmelitsch J,
    9. Hager E,
    10. Hess CF,
    11. Karstens J-H,
    12. Liersch T,
    13. Schmidberger H,
    14. Raab R,
    15. German Rectal Cancer Study Group
    : Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351: 1731-1740, 2004. PMID: 15496622. DOI: 10.1056/NEJMoa040694
    OpenUrlCrossRefPubMed
  12. ↵
    1. Geva R,
    2. Davidovics H,
    3. Soyfer S,
    4. Pelles-Avraham S,
    5. Klausner JM,
    6. Inbar M,
    7. Tulchinsky H
    : Does residual microscopic disease after chemoradiotherapy for locally advanced rectal cancer translate into a good clinical outcome? Colorectal Dis 19: 237-242, 2017. PMID: 27474791. DOI: 10.1111/codi.13474
    OpenUrl
  13. ↵
    1. Maggiori L,
    2. Bretagnol F,
    3. Aslam MI,
    4. Guedj N,
    5. Zappa M,
    6. Ferron M,
    7. Panis Y
    : Does pathologic response of rectal cancer influence postoperative morbidity after neoadjuvant radiochemotherapy and total mesorectal excision? Surgery 155: 468-475, 2014. PMID: 24439750. DOI: 10.1016/j.surg.2013. 10.020
    OpenUrl
  14. ↵
    1. Landi F,
    2. Espín E,
    3. Rodrigues V,
    4. Vallribera F,
    5. Martinez A,
    6. Charpy C,
    7. Brunetti F,
    8. Azoulay D,
    9. de'Angelis N
    : Pathologic response grade after long-course neoadjuvant chemoradiation does not influence morbidity in locally advanced mid-low rectal cancer resected by laparoscopy. Int J Colorectal Dis 32: 255-264, 2017. PMID: 27757541. DOI: 10.1007/s00384-016-2685-4
    OpenUrl
  15. ↵
    1. Wolthuis AM,
    2. Penninckx F,
    3. Haustermans K,
    4. De Hertogh G,
    5. Fieuws S,
    6. Van Cutsem E,
    7. D'Hoore A
    : Impact of interval between neoadjuvant chemoradiotherapy and TME for locally advanced rectal cancer on pathologic response and oncologic outcome. Ann Surg Oncol 19: 2833-2841, 2012. PMID: 22451236. DOI: 10.1245/s10434-012-2327-1
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bretagnol F,
    2. Panis Y,
    3. Rullier E,
    4. Rouanet P,
    5. Berdah S,
    6. Dousset B,
    7. Portier G,
    8. Benoist S,
    9. Chipponi J,
    10. Vicaut E,
    11. French Research Group of Rectal Cancer Surgery (GRECCAR)
    : Rectal cancer surgery with or without bowel preparation: The French GRECCAR III multicenter single-blinded randomized trial. Ann Surg 252: 863-868, 2010. PMID: 21037443. DOI: 10.1097/SLA.0b013e3181fd8ea9
    OpenUrlCrossRefPubMed
  17. ↵
    1. Quirke P,
    2. Durdey P,
    3. Dixon MF,
    4. Williams NS
    : Local recurrence of rectal adenocarcinoma due to inadequate surgical resection. Histopathological study of lateral tumour spread and surgical excision. Lancet Lond Engl 2: 996-999, 1986. PMID: 2430152. DOI: 10.1016/s0140-6736(86)92612-7
    OpenUrl
  18. ↵
    1. Washington MK,
    2. Berlin J,
    3. Branton P,
    4. Burgart LJ,
    5. Carter DK,
    6. Fitzgibbons PL,
    7. Halling K,
    8. Frankel W,
    9. Jessup J,
    10. Kakar S,
    11. Minsky B,
    12. Nakhleh R,
    13. Compton CC,
    14. Members of the Cancer Committee,
    15. College of American Pathologists
    : Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med 133: 1539-1551, 2009. PMID: 19792043. DOI: 10.1043/1543-2165-133.10.1539
    OpenUrlPubMed
  19. ↵
    1. Dindo D,
    2. Demartines N,
    3. Clavien P-A
    : Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240: 205-213, 2004. PMID: 15273542. DOI: 10.1097/01.sla.0 000133083.54934.ae
    OpenUrlCrossRefPubMed
  20. ↵
    1. Rahbari NN,
    2. Weitz J,
    3. Hohenberger W,
    4. Heald RJ,
    5. Moran B,
    6. Ulrich A,
    7. Holm T,
    8. Wong WD,
    9. Tiret E,
    10. Moriya Y,
    11. Laurberg S,
    12. den Dulk M,
    13. van de Velde C,
    14. Büchler MW
    : Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 147: 339-351, 2010. PMID: 20004450. DOI: 10.1016/j.surg.2009.10.012
    OpenUrlCrossRefPubMed
  21. ↵
    1. Hain E,
    2. Maggiori L,
    3. Manceau G,
    4. Zappa M,
    5. Prost à la Denise J,
    6. Panis Y
    : Persistent asymptomatic anastomotic leakage after laparoscopic sphincter-saving surgery for rectal cancer: Can diverting stoma be reversed safely at 6 months? Dis Colon Rectum 59: 369-376, 2016. PMID: 27050598. DOI: 10.1097/DCR.0000000000000568
    OpenUrl
  22. ↵
    1. Emmertsen KJ,
    2. Laurberg S
    : Low anterior resection syndrome score: development and validation of a symptom-based scoring system for bowel dysfunction after low anterior resection for rectal cancer. Ann Surg 255: 922-928, 2012. PMID: 22504191. DOI: 10.1097/SLA.0b013e31824f1c21
    OpenUrlPubMed
  23. ↵
    1. Vaizey CJ,
    2. Carapeti E,
    3. Cahill JA,
    4. Kamm MA
    : Prospective comparison of faecal incontinence grading systems. Gut 44: 77-80, 1999. PMID: 9862829. DOI: 10.1136/gut.44.1.77
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Von Elm E,
    2. Altman DG,
    3. Egger M,
    4. Pocock SJ,
    5. Gøtzsche PC,
    6. Vandenbroucke JP
    : The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 147: 573-577, 2007. PMID: 18064739. DOI: 10.1016/S0140-6736(07)61602-X
    OpenUrlCrossRefPubMed
  25. ↵
    1. Rödel C,
    2. Hofheinz R,
    3. Fokas E
    : Rectal cancer: Neoadjuvant chemoradiotherapy. Best Pract Res Clin Gastroenterol 30: 629-639, 2016. PMID: 27644910. DOI: 10.1016/j.bpg.2016.06.004
    OpenUrl
  26. ↵
    1. Janjan NA,
    2. Crane C,
    3. Feig BW,
    4. Cleary K,
    5. Dubrow R,
    6. Curley S,
    7. Vauthey JN,
    8. Lynch P,
    9. Ellis LM,
    10. Wolff R,
    11. Lenzi R,
    12. Abbruzzese J,
    13. Pazdur R,
    14. Hoff PM,
    15. Allen P,
    16. Brown T,
    17. Skibber J
    : Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer. Am J Clin Oncol 24: 107-112, 2001. PMID: 11319280.
    OpenUrlCrossRefPubMed
  27. ↵
    1. Dworak O,
    2. Keilholz L,
    3. Hoffmann A
    : Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12: 19-23, 1997. PMID: 9112145.
    OpenUrlCrossRefPubMed
  28. ↵
    1. Wheeler JMD,
    2. Warren BF,
    3. Mortensen NJM,
    4. Ekanyaka N,
    5. Kulacoglu H,
    6. Jones AC,
    7. George BD,
    8. Kettlewell MGW
    : Quantification of histologic regression of rectal cancer after irradiation: a proposal for a modified staging system. Dis Colon Rectum 45: 1051-1056, 2002. PMID: 12195189.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Farnault B,
    2. Moureau-Zabotto L,
    3. de Chaisemartin C,
    4. Esterni B,
    5. Lelong B,
    6. Viret F,
    7. Giovannini M,
    8. Monges G,
    9. Delpero J-R,
    10. Bories E,
    11. Turrini O,
    12. Viens P,
    13. Resbeut M
    : Predictive factors of tumour response after neoadjuvant chemoradiation for locally advanced rectal cancer and correlation of these factors with survival. Cancer Radiother 15: 279-286, 2011. PMID: 21515083. DOI: 10.1016/j.canrad.2011.01.005
    OpenUrlPubMed
  30. ↵
    1. Das P,
    2. Skibber JM,
    3. Rodriguez-Bigas MA,
    4. Feig BW,
    5. Chang GJ,
    6. Hoff PM,
    7. Eng C,
    8. Wolff RA,
    9. Janjan NA,
    10. Delclos ME,
    11. Krishnan S,
    12. Levy LB,
    13. Ellis LM,
    14. Crane CH
    : Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. Am J Clin Oncol 29: 219-224, 2006. PMID: 16755173. DOI: 10.1097/01.coc.0000 2149 30.78200.4a
    OpenUrlCrossRefPubMed
  31. ↵
    1. Losi L,
    2. Luppi G,
    3. Gavioli M,
    4. Iachetta F,
    5. Bertolini F,
    6. D'Amico R,
    7. Jovic G,
    8. Bertoni F,
    9. Falchi AM,
    10. Conte PF
    : Prognostic value of Dworak grade of regression (GR) in patients with rectal carcinoma treated with preoperative radiochemotherapy. Int J Colorectal Dis 21: 645-651, 2006. PMID: 16317549. DOI: 10.1007/s00384-005-0061-x
    OpenUrlCrossRefPubMed
  32. ↵
    1. Yeo S-G,
    2. Kim DY,
    3. Kim TH,
    4. Chang HJ,
    5. Oh JH,
    6. Park W,
    7. Choi DH,
    8. Nam H,
    9. Kim J-S,
    10. Cho M-J,
    11. Kim JH,
    12. Park J-H,
    13. Kang MK,
    14. Koom WS,
    15. Kim J-S,
    16. Nam T-K,
    17. Chie EK,
    18. Kim JS,
    19. Lee K-J
    : Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer: long-term outcomes and prognostic significance of pathologic nodal status (KROG 09-01). Ann Surg 252: 998-1004, 2010. PMID: 21107110. DOI: 10.1097/SLA.0b013e3 181f3f1b1
    OpenUrlCrossRefPubMed
  33. ↵
    1. Maretto I,
    2. Pomerri F,
    3. Pucciarelli S,
    4. Mescoli C,
    5. Belluco E,
    6. Burzi S,
    7. Rugge M,
    8. Muzzio PC,
    9. Nitti D
    : The potential of restaging in the prediction of pathologic response after preoperative chemoradiotherapy for rectal cancer. Ann Surg Oncol 14: 455-461, 2007. PMID: 17139456. DOI: 10.1245/s10434-006-9269-4
    OpenUrlCrossRefPubMed
  34. ↵
    1. Kalady MF,
    2. de Campos-Lobato LF,
    3. Stocchi L,
    4. Geisler DP,
    5. Dietz D,
    6. Lavery IC,
    7. Fazio VW
    : Predictive factors of pathologic complete response after neoadjuvant chemoradiation for rectal cancer. Ann Surg 250: 582-589, 2009. PMID: 19710605. DOI: 10.1097/SLA.0b013e3181b91e63
    OpenUrlPubMed
  35. ↵
    1. Tulchinsky H,
    2. Shmueli E,
    3. Figer A,
    4. Klausner JM,
    5. Rabau M
    : An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol 15: 2661-2667, 2008. PMID: 18389322. DOI: 10.1245/s10434-008-9892-3
    OpenUrlCrossRefPubMed
  36. ↵
    1. Stein DE,
    2. Mahmoud NN,
    3. Anné PR,
    4. Rose DG,
    5. Isenberg GA,
    6. Goldstein SD,
    7. Mitchell E,
    8. Fry RD
    : Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 46: 448-453, 2003. PMID: 12682535. DOI: 10.1097/01.DCR.0000059325.26893.B3
    OpenUrlCrossRefPubMed
  37. ↵
    1. Habr-Gama A,
    2. Perez RO,
    3. Nadalin W,
    4. Sabbaga J,
    5. Ribeiro U,
    6. Silva e Sousa AH,
    7. Campos FG,
    8. Kiss DR,
    9. Gama-Rodrigues J
    : Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240: 711-717; discussion 717-718, 2004. PMID: 15383798. DOI: 10.1097/01.sla.0000141194.27992.32
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Anticancer Research: 39 (9)
Anticancer Research
Vol. 39, Issue 9
September 2019
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Complete Pathological Response Following Radiochemotherapy for Locally Advanced Rectal Cancer: Short and Long-term Outcome
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Complete Pathological Response Following Radiochemotherapy for Locally Advanced Rectal Cancer: Short and Long-term Outcome
OTHMAN ISKANDER, LISE COURTOT, NICOLAS TABCHOURI, ALICE ARTUS, NICOLAS MICHOT, OLIVIER MULLER, URS PABST-GIGER, PASCAL BOURLIER, AURORE KRAEMER-BUCUR, THIERRY LECOMTE, SERGE GUYETANT, SOPHIE CHAPET, GILLES CALAIS, EPHREM SALAMÉ, MEHDI OUAÏSSI
Anticancer Research Sep 2019, 39 (9) 5105-5113; DOI: 10.21873/anticanres.13705

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Complete Pathological Response Following Radiochemotherapy for Locally Advanced Rectal Cancer: Short and Long-term Outcome
OTHMAN ISKANDER, LISE COURTOT, NICOLAS TABCHOURI, ALICE ARTUS, NICOLAS MICHOT, OLIVIER MULLER, URS PABST-GIGER, PASCAL BOURLIER, AURORE KRAEMER-BUCUR, THIERRY LECOMTE, SERGE GUYETANT, SOPHIE CHAPET, GILLES CALAIS, EPHREM SALAMÉ, MEHDI OUAÏSSI
Anticancer Research Sep 2019, 39 (9) 5105-5113; DOI: 10.21873/anticanres.13705
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Tumor microRNAs Identified by Small RNA Sequencing as Potential Response Predictors in Locally Advanced Rectal Cancer Patients Treated With Neoadjuvant Chemoradiotherapy
  • Google Scholar

More in this TOC Section

  • Triage Process at Endoscopy With ColonView Fecal Immunochemical Test (FIT) Will Enhance Diagnostic Accuracy (DA) of Colorectal Cancer Screening
  • Laparoscopic Colorectal Cancer Surgery for Patients With Severe Chronic Heart Failure
  • Clinical Impact of Prehabilitation on Elective Laparoscopic Surgery in Frail Octogenarians With Colorectal Cancer
Show more Clinical Studies

Similar Articles

Keywords

  • Rectal carcinoma
  • radiochemotherapy
  • pathological response
Anticancer Research

© 2023 Anticancer Research

Powered by HighWire